Molbio Diagnostics gets SEBI approval for INR 200 Cr IPO

The company plans to leverage the proceeds from the fresh issue of capital primarily towards expanding its research and development capabilities

Goa-based molecular diagnostics firm Molbio Diagnostics has received the regulatory approvals from the Securities and Exchange Board of India (SEBI) to launch its initial public offering (IPO), according to recent filings.

Under its proposed DRHP, filed in August 2025, the IPO shall comprise a fresh issue of equity shares worth INR 200 crore, along with an offer-for-sale (OFS) of up to 1.25 crore existing shares by current shareholders, including Temasek and Motilal Oswal Private Equity firms.

The company plans to leverage the proceeds from the fresh issue of capital primarily towards expanding its research and development capabilities, including building a new R&D facility and a “Center of Excellence”, and upgrading manufacturing capacity across its plants.

Molbio reported INR 1,020 crore in revenue and INR 138.5 crore profit in FY25.

Founded in 2000, Molbio Diagnostics develops and markets molecular diagnostic solutions covering more than 30 diseases, including tuberculosis, COVID-19, HIV, HPV, and hepatitis.

Its flagship product, the battery-operated “Truenat” platform, is a portable PCR-based solution designed for point-of-care testing in resource-limited settings.

The technology is patented in over 100 countries and has been widely deployed in public health and disease-control programmes.

Currently, the company operates five manufacturing facilities in India, two in Goa, one in Visakhapatnam, and two in Bengaluru, producing devices, test kits, and radiology equipment through its subsidiary, Prognosys Medical Systems.

Stay tuned for more such updates on Digital Health News